Enhanced Efficacy Through Optimization of Hemoporfin-Photodynamic Therapy Parameters in Port-Wine Stains
NCT07353385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2026-01-20
Summary
1. Background and Objectives Port-wine stain (PWS) is a congenital capillary malformation located in the upper dermis. Hematoporphyrin monomethyl ether (HMME)-mediated photodynamic therapy (PDT) has been established as a primary and effective treatment for PWS in China. However, treatment parameters, particularly irradiance and irradiation duration, vary widely in clinical practice based on physician experience, with a lack of evidence from controlled trials to guide optimization. The efficacy of PDT relies on a type II photochemical reaction, which is oxygen-dependent. High irradiance may lead to rapid oxygen depletion in the treatment area, potentially limiting therapeutic outcomes. This prospective, randomized controlled trial aims to compare the efficacy and safety of a low-irradiance, prolonged-duration protocol versus a high-irradiance, shorter-duration protocol in HMME-PDT for PWS, while maintaining an identical total light dose.
2. Study Design
This was a single-center, randomized controlled, single-blind trial. The study protocol was approved by the Ethics Committee of The Second Affiliated Hospital of Xi'an Jiaotong University (Approval No. 2024219). A total of 33 pediatric patients (aged 3-12 years) with facial or neck PWS were enrolled and randomly assigned to one of two groups:
Low-Power Group (n=15): Received irradiation at 75 mW/cm² for 19 minutes per spot.
High-Power Group (n=18): Received irradiation at 84 mW/cm² for 17 minutes per spot.
Both groups received a single session of HMME-PDT with the same total light dose. All patients received an intravenous infusion of Hemoporfin at a dose of 5.0 mg/kg, followed by irradiation with a 532-nm LED green light.
3. Primary evaluation indicators
The primary efficacy endpoint was lesion clearance assessed at the 3-month follow-up using three independent methods:
Blinded Quartile Grading: Performed by two independent dermatologists based on high-resolution photographs.
Quantitative Lesion Area Reduction: The percentage reduction in the PWS area was calculated from VISIA complexion analysis system "redness" images using ImageJ software.
Erythema Index (EI) Analysis: The relative change in the EI (ΔEI%) between the lesion and normal skin was quantified.
Conditions
- Port Wine Stains
Interventions
- RADIATION
-
irradiation at 84 mW/cm² for 17 minutes per spot
Patients were positioned appropriately, with pediatric patients secured using a restraining bed. The target lesions were fully exposed (shaved if necessary), cleansed, disinfected, and the surrounding healthy skin was shielded with black cloth. The laser parameters and handpiece position were adjusted to ensure the lesion remained within the effective irradiation field. Under dim light, a prepared Hemoporfin (Shanghai Fudan Zhangjiang Pharmaceutical Co., Ltd.) solution was diluted to 20 mL at a dosage of 5.0 mg/kg and administered via infusion pump at a controlled rate within 5 minutes. Approximately 3 minutes post-initiation of infusion, irradiation with a 532-nm LED green light (Wuhan Yage Optoelectronic Technology Co., Ltd.) commenced. To maintain an identical total light dose between groups, the high-power group received 84 mW/cm² for 17 minutes per spot.
- RADIATION
-
irradiation at 75 mW/cm² for 19 minutes per spot
Patients were positioned appropriately, with pediatric patients secured using a restraining bed. The target lesions were fully exposed (shaved if necessary), cleansed, disinfected, and the surrounding healthy skin was shielded with black cloth. The laser parameters and handpiece position were adjusted to ensure the lesion remained within the effective irradiation field. Under dim light, a prepared Hemoporfin (Shanghai Fudan Zhangjiang Pharmaceutical Co., Ltd.) solution was diluted to 20 mL at a dosage of 5.0 mg/kg and administered via infusion pump at a controlled rate within 5 minutes. Approximately 3 minutes post-initiation of infusion, irradiation with a 532-nm LED green light (Wuhan Yage Optoelectronic Technology Co., Ltd.) commenced. To maintain an identical total light dose between groups, the low-power group received 75 mW/cm² for 19 minutes per spot.
Sponsors & Collaborators
-
Second Affiliated Hospital of Xi'an Jiaotong University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 3 Years
- Max Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2025-03-30
- Completion
- 2025-06-01
Countries
- China
Study Locations
More Related Trials
-
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.
NCT00830466 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.
NCT00800722 ·Status: COMPLETED ·Phase: PHASE1
-
Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
NCT00585247 ·Status: COMPLETED ·Phase: NA
-
Pretreatments of the Skin Prior to PDT
NCT02372370 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus
NCT02214706 ·Status: TERMINATED ·Phase: NA
-
Treatment of Naevus Flammeus Using Intense Pulsed Light and Pulsed Dye Laser
NCT00365118 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of STBF Photodynamic Therapy for Moderate and Severe Acne Vulgaris
NCT05245045 ·Status: UNKNOWN ·Phase: NA
-
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
NCT00049959 ·Status: TERMINATED ·Phase: PHASE3
-
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne
NCT01490736 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
NCT01682811 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser.
NCT03885895 ·Status: UNKNOWN ·Phase: PHASE1
-
To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
NCT03864315 ·Status: COMPLETED ·Phase: NA
-
A Photodynamic Therapy for Treatment of Actinic Keratoses
NCT00558688 ·Status: COMPLETED ·Phase: NA
-
Multiclear Treatment for Striae Distensae - A Pilot Study
NCT02126566 ·Status: COMPLETED ·Phase: PHASE2
-
Photographing the Skin During Photodynamic Therapy
NCT03167762 ·Status: COMPLETED ·Phase: NA
-
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
NCT03697590 ·Status: COMPLETED ·Phase: PHASE4
-
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Actinic Keratosis
NCT04396184 ·Status: UNKNOWN ·Phase: NA
-
Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
NCT01097850 ·Status: WITHDRAWN ·Phase: PHASE2
-
Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder
NCT03578315 ·Status: COMPLETED ·Phase: NA
-
The Effects of Aldara as an Adjunct to Laser Treatment
NCT00979550 ·Status: TERMINATED ·Phase: PHASE2
-
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
NCT01491620 ·Status: COMPLETED ·Phase: NA
-
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
NCT02728388 ·Status: TERMINATED ·Phase: PHASE2
-
Combined Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders
NCT06911281 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of High-Intensity Macrofocused Ultrasound for Solar Lentigo in Chinese Population
NCT06288607 ·Status: COMPLETED
-
Photodynamic Therapy and Microvesicles
NCT03960125 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1